Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex

Thrombosis and Haemostasis

Volumn 78, Issue 3, 1997, Pages 1138-1141

  Sato, Yuichiro ^a   Asada, Yujiro ^a   Marutsuka, Kousuke ^a   Hatakeyama, Kinta ^b   Kamikubo, Yuichi ^b   Sumiyoshi, Akinobu ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; HIRUDIN; PLATELET DERIVED GROWTH FACTOR BB; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CELL MIGRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0030799201     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657700     Document Type: Article

References (23)

1. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66: 67-79,
2. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992;12: 1111-21.
3. Lupu F, Lupu C, Scully M, Das S, Kakkar V. Localization of tissue factor pathway inhibitor in normal and atherosclerotic vessels. Thromb Haemost 1995; 73: 1184 (Abst.)
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
5. Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993; 21: S21-S49.
6. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-20.
7. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-92.
8. Ruf W, Rehemtulla A, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158-66.
9. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
10. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91; 2253-9.
11. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high dose factor VIIa in hemophilia. Blood 1994; 83: 38-42.
12. Reuning U, Preissner KT, Müller-Berghaus G. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa. Thromb Haemost 1993; 69: 197-204.
13. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
14. Bornfeldt KE. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc Med 1996; 6: 143-51.
15. Broze GJ. Jr Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
16. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
17. Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. J Biol Chem 1992; 267: 876-82.
18. Hamamoto T, Yamamoto M, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). J Biol Chem 1993; 268: 8704-10.
19. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
20. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
21. Bregengård C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag Fibrinol 1993; 4: 699-706.
22. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.
23. Camerer E, Kolstø A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.